Zydelig
Drug
Gilead Sciences Inc
Total Payments
$6.6M
Transactions
3,554
Doctors
615
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $5,500 | 1 | 0 |
| 2023 | $18,380 | 1 | 0 |
| 2022 | $12,040 | 2 | 0 |
| 2021 | $326,776 | 9 | 1 |
| 2020 | $163,974 | 24 | 1 |
| 2019 | $577,991 | 257 | 105 |
| 2018 | $2.0M | 1,474 | 241 |
| 2017 | $3.6M | 1,786 | 374 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.4M | 592 | 66.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.0M | 323 | 15.7% |
| Consulting Fee | $739,998 | 260 | 11.2% |
| Travel and Lodging | $345,888 | 1,035 | 5.2% |
| Food and Beverage | $71,854 | 1,344 | 1.1% |
Payments by Type
Research
$4.4M
592 transactions
General
$2.2M
2,962 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase II Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL | Gilead Sciences Inc | $585,012 | 0 |
| A Pilot study of Zydelig in Patients with B-cell Malignancies as Post-Autologous Transplant Remission Maintenance | Gilead Sciences, Inc. | $454,664 | 0 |
| A Phase 1b Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Idelalisib in Subjects Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis with Progressive or Relapsed Disease | Gilead Sciences Inc | $310,692 | 0 |
| A Pilot study of Zydelig in Patients with B-cell Malignancies as Post-Autologous Transplant Remission Maintenance | Gilead Sciences Inc | $296,254 | 0 |
| A Phase 3, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS 1101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia | Gilead Sciences, Inc. | $216,359 | 0 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evalutating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | Gilead Sciences, Inc. | $215,231 | 0 |
| Idelalisib post allogeneic BMT in B cell derived malignancies: a phase 1 toxicity trial | Gilead Sciences, Inc. | $201,307 | 0 |
| A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single Agent Idelalisib (GS-1101) for Previously Treated Chronic Lymphocytic Leukemia. A Companion Trial to Study GS-US-312-0116: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS 1101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia | Gilead Sciences Inc | $181,359 | 0 |
| A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia | Gilead Sciences, Inc. | $173,803 | 0 |
| A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia | Gilead Sciences Inc | $152,681 | 0 |
| A Phase 3, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS 1101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia | Gilead Sciences Inc | $140,675 | 0 |
| A Phase 1b/2 Study of Idelalisib in Combination with BI 836826 in Subjects with Chronic Lymphocytic Leukemia | Gilead Sciences Inc | $137,497 | 0 |
| A Phase 1b Study of Single Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Subjects with Metastatic Pancreatic Ductal Adenocarcinoma | Gilead Sciences, Inc. | $131,739 | 0 |
| A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single Agent Idelalisib (GS-1101) for Previously Treated Chronic Lymphocytic Leukemia. A Companion Trial to Study GS-US-312-0116: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS 1101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia | Gilead Sciences, Inc. | $126,427 | 0 |
| Idelalisib post allogeneic BMT in B cell derived malignancies: a phase 1 toxicity trial | Gilead Sciences Inc | $105,684 | 0 |
| Phase II study of idelalisib for patients with relapsed or refractory Waldenstrom Macroglobulinemia | Gilead Sciences Inc | $97,350 | 0 |
| Phase 1 Trial of Rituximab, Idelalisib, and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (RIVe-CLL) | Gilead Sciences, Inc. | $97,148 | 0 |
| A Phase 2 Single Arm Study to Investigate the Safety and Clinical Activity of CAL-101 alone and in Combination With Rituximab in Elderly Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Gilead Sciences Inc | $94,007 | 0 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evalutating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | Gilead Sciences Inc | $93,414 | 0 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS 1101) in Combination with Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia | Gilead Sciences, Inc. | $89,919 | 0 |
Top Doctors Receiving Payments for Zydelig — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Hematology & Oncology | Houston, TX | $8,970 | 10 |
| , MD | Medical Oncology | Chicago, IL | $8,540 | 14 |
| , MD | Hematology | Indianapolis, IN | $7,971 | 9 |
| , MD | Internal Medicine | Bethesda, MD | $7,803 | 8 |
| Peter Riedell | Hematology & Oncology | Chicago, IL | $7,734 | 8 |
| , MD | Hematology & Oncology | Aurora, CO | $7,705 | 13 |
| , M.D | Medical Oncology | Houston, TX | $7,664 | 13 |
| , MD | Hematology & Oncology | Philadelphia, PA | $7,663 | 15 |
| , MD | Internal Medicine | Philadelphia, PA | $7,500 | 3 |
| , MD | Hematology & Oncology | Shreveport, LA | $7,464 | 10 |
| , M.D | Hematology & Oncology | Miami, FL | $7,452 | 7 |
| , MD | Hematology & Oncology | Philadelphia, PA | $7,206 | 10 |
| Michael Bishop | Hematology & Oncology | Chicago, IL | $6,964 | 10 |
| , DO | Student in an Organized Health Care Education/Training Program | Boise, ID | $6,828 | 9 |
| , M.D | Hematology & Oncology | Charlottesville, VA | $6,588 | 8 |
| , MD, PHD | Hematology & Oncology | Duarte, CA | $6,522 | 7 |
| , MD | Internal Medicine | Rochester, NY | $6,519 | 11 |
| , M.D | Hematology & Oncology | Mesquite, TX | $6,341 | 9 |
| , MD | Hematology & Oncology | Philadelphia, PA | $6,093 | 7 |
| , D.O., M.P.H | Hematology & Oncology | Scottsdale, AZ | $6,036 | 7 |
| , M.D | Internal Medicine | Colton, CA | $6,029 | 13 |
| , MD | Hematology & Oncology | Webster, TX | $6,020 | 12 |
| , MD | Medical Oncology | Saint Louis, MO | $5,946 | 4 |
| , D.O | Hematology & Oncology | Royal Oak, MI | $5,936 | 8 |
| , MD | Hematology & Oncology | Williamsville, NY | $5,905 | 8 |
Ad
Manufacturing Companies
- Gilead Sciences Inc $3.5M
- Gilead Sciences, Inc. $3.1M
Product Information
- Type Drug
- Total Payments $6.6M
- Total Doctors 615
- Transactions 3,554
About Zydelig
Zydelig is a drug associated with $6.6M in payments to 615 healthcare providers, recorded across 3,554 transactions in the CMS Open Payments database. The primary manufacturer is Gilead Sciences Inc.
Payment data is available from 2017 to 2024. In 2024, $5,500 was paid across 1 transactions to 0 doctors.
The most common payment nature for Zydelig is "Unspecified" ($4.4M, 66.8% of total).
Zydelig is associated with 20 research studies, including "A Phase II Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL" ($585,012).